Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance

Jonathan Evrard; Laure Morimont; Marie Didembourg; Hélène Haguet; Romain Siriez; Jean-Michel Dogné; Jonathan Douxfils

doi:10.1111/ijlh.13427

Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance

Jonathan Evrard, Laure Morimont, Marie Didembourg, Hélène Haguet, Romain Siriez, Jean-Michel Dogné, Jonathan Douxfils

University of Namur

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: Activated protein C (APC) resistance is a major risk factor of venous thrombosis which may be acquired by hormonal therapy or other causes. The FibWave, a sensitive global clot-based assay design to analyze the coagulation kinetics in plasma, may be a good candidate to assess this prothrombotic state. This study aims to assess the suitability of the FibWave to differentiate the coagulation kinetics of women on oral contraceptives.

MATERIALS AND METHODS: Fifty-four healthy volunteers were divided into 5 groups: men [n = 13], women not using hormonal contraception [n = 12], women using second [n = 12] or third generation [n = 12] combined oral contraceptives, and women using progestin only contraceptive [n = 5]. Patients with coagulation abnormalities were also assessed [n = 8]. The APC resistance was assessed on the FibWave using exogenous APC or Protac, and on the Calibrated Automated Thrombogram using the ETP-based APC resistance assay.

RESULTS: Either in presence or in absence of APC or Protac, the FibWave was able to detect a hypercoagulable state in plasma samples. All combined oral contraceptives showed a lower FW-Max1 , FW-Max2, and FW-Min2 percentage of inhibition and a lower FW-Ttpeak ratio than the other groups. The sensitivity of the FibWave was similar to the one of the ETP-based APC resistance assay.

CONCLUSION: The FibWave is able to differentiate APC resistance levels observed in women on combined oral contraceptive. The FW-Max1 , FW-Max2, and to a lesser degree FW-Min2 were identified as the most sensitive parameters with a similar performance to the ETP-based APC resistance assay.

Original language	English
Pages (from-to)	802-812
Number of pages	11
Journal	International Journal of Laboratory Hematology
Volume	43
Issue number	4
Early online date	2020
DOIs	https://doi.org/10.1111/ijlh.13427
Publication status	Published - Aug 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ijlh.13427

Embargoed Document

5832-2020-Evrard
Final published version, 1.38 MB

1 Finished
1 Active

The CAF project - a new tool for the assessment of the clot formation
Douxfils, J. (Supervisor), Dogne, J.-M. (CoI), Evrard, J. (Researcher), Morimont, L. (Researcher) & Maloteau, V. (Technician)
1/09/18 → …
Project: Research
The HIC Project : Evaluation of hormone-induced coagulopathy
Dogne, J.-M. (Supervisor), Douxfils, J. (Supervisor), Morimont, L. (Researcher), Didembourg, M. (Researcher) & Evrard, J. (Researcher)
1/09/19 → 31/08/23
Project: Research

Development of the FibWave, an improved clot waveform analysis for the assessment of hemostasis
Evrard, J. (Author), Douxfils, J. (Supervisor), Dogne, J.-M. (Co-Supervisor), Lucas, S. (Jury), MASEREEL, B. (Jury), MULLIER, F. (Jury), Demeure, F. (Jury), Verhamme, P. B. (Jury), TEN CATE, H. (Jury) & Lebreton, A. (Jury), 11 Apr 2023
Student thesis: Doc types › Doctor of Biomedical and Pharmaceutical Sciences

File

Cite this

@article{9a532c9ed5564012a842a1b6adbfab18,

title = "Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance",

abstract = "INTRODUCTION: Activated protein C (APC) resistance is a major risk factor of venous thrombosis which may be acquired by hormonal therapy or other causes. The FibWave, a sensitive global clot-based assay design to analyze the coagulation kinetics in plasma, may be a good candidate to assess this prothrombotic state. This study aims to assess the suitability of the FibWave to differentiate the coagulation kinetics of women on oral contraceptives.MATERIALS AND METHODS: Fifty-four healthy volunteers were divided into 5 groups: men [n = 13], women not using hormonal contraception [n = 12], women using second [n = 12] or third generation [n = 12] combined oral contraceptives, and women using progestin only contraceptive [n = 5]. Patients with coagulation abnormalities were also assessed [n = 8]. The APC resistance was assessed on the FibWave using exogenous APC or Protac, and on the Calibrated Automated Thrombogram using the ETP-based APC resistance assay.RESULTS: Either in presence or in absence of APC or Protac, the FibWave was able to detect a hypercoagulable state in plasma samples. All combined oral contraceptives showed a lower FW-Max1 , FW-Max2, and FW-Min2 percentage of inhibition and a lower FW-Ttpeak ratio than the other groups. The sensitivity of the FibWave was similar to the one of the ETP-based APC resistance assay.CONCLUSION: The FibWave is able to differentiate APC resistance levels observed in women on combined oral contraceptive. The FW-Max1 , FW-Max2, and to a lesser degree FW-Min2 were identified as the most sensitive parameters with a similar performance to the ETP-based APC resistance assay.",

author = "Jonathan Evrard and Laure Morimont and Marie Didembourg and H{\'e}l{\`e}ne Haguet and Romain Siriez and Jean-Michel Dogn{\'e} and Jonathan Douxfils",

note = "{\textcopyright} 2020 John Wiley & Sons Ltd.",

year = "2021",

month = aug,

doi = "10.1111/ijlh.13427",

language = "English",

volume = "43",

pages = "802--812",

journal = "International Journal of Laboratory Hematology",

issn = "1751-5521",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance

AU - Evrard, Jonathan

AU - Morimont, Laure

AU - Didembourg, Marie

AU - Haguet, Hélène

AU - Siriez, Romain

AU - Dogné, Jean-Michel

AU - Douxfils, Jonathan

PY - 2021/8

Y1 - 2021/8

N2 - INTRODUCTION: Activated protein C (APC) resistance is a major risk factor of venous thrombosis which may be acquired by hormonal therapy or other causes. The FibWave, a sensitive global clot-based assay design to analyze the coagulation kinetics in plasma, may be a good candidate to assess this prothrombotic state. This study aims to assess the suitability of the FibWave to differentiate the coagulation kinetics of women on oral contraceptives.MATERIALS AND METHODS: Fifty-four healthy volunteers were divided into 5 groups: men [n = 13], women not using hormonal contraception [n = 12], women using second [n = 12] or third generation [n = 12] combined oral contraceptives, and women using progestin only contraceptive [n = 5]. Patients with coagulation abnormalities were also assessed [n = 8]. The APC resistance was assessed on the FibWave using exogenous APC or Protac, and on the Calibrated Automated Thrombogram using the ETP-based APC resistance assay.RESULTS: Either in presence or in absence of APC or Protac, the FibWave was able to detect a hypercoagulable state in plasma samples. All combined oral contraceptives showed a lower FW-Max1 , FW-Max2, and FW-Min2 percentage of inhibition and a lower FW-Ttpeak ratio than the other groups. The sensitivity of the FibWave was similar to the one of the ETP-based APC resistance assay.CONCLUSION: The FibWave is able to differentiate APC resistance levels observed in women on combined oral contraceptive. The FW-Max1 , FW-Max2, and to a lesser degree FW-Min2 were identified as the most sensitive parameters with a similar performance to the ETP-based APC resistance assay.

AB - INTRODUCTION: Activated protein C (APC) resistance is a major risk factor of venous thrombosis which may be acquired by hormonal therapy or other causes. The FibWave, a sensitive global clot-based assay design to analyze the coagulation kinetics in plasma, may be a good candidate to assess this prothrombotic state. This study aims to assess the suitability of the FibWave to differentiate the coagulation kinetics of women on oral contraceptives.MATERIALS AND METHODS: Fifty-four healthy volunteers were divided into 5 groups: men [n = 13], women not using hormonal contraception [n = 12], women using second [n = 12] or third generation [n = 12] combined oral contraceptives, and women using progestin only contraceptive [n = 5]. Patients with coagulation abnormalities were also assessed [n = 8]. The APC resistance was assessed on the FibWave using exogenous APC or Protac, and on the Calibrated Automated Thrombogram using the ETP-based APC resistance assay.RESULTS: Either in presence or in absence of APC or Protac, the FibWave was able to detect a hypercoagulable state in plasma samples. All combined oral contraceptives showed a lower FW-Max1 , FW-Max2, and FW-Min2 percentage of inhibition and a lower FW-Ttpeak ratio than the other groups. The sensitivity of the FibWave was similar to the one of the ETP-based APC resistance assay.CONCLUSION: The FibWave is able to differentiate APC resistance levels observed in women on combined oral contraceptive. The FW-Max1 , FW-Max2, and to a lesser degree FW-Min2 were identified as the most sensitive parameters with a similar performance to the ETP-based APC resistance assay.

U2 - 10.1111/ijlh.13427

DO - 10.1111/ijlh.13427

M3 - Article

C2 - 33314736

SN - 1751-5521

VL - 43

SP - 802

EP - 812

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

IS - 4

ER -

Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance

Abstract

UN SDGs

Access to Document

Embargoed Document

Fingerprint

Projects

The CAF project - a new tool for the assessment of the clot formation

The HIC Project : Evaluation of hormone-induced coagulopathy

Student theses

Development of the FibWave, an improved clot waveform analysis for the assessment of hemostasis

Cite this